Maugeri Andrea, Barchitta Martina, Fallico Matteo, Castellino Niccolò, Reibaldi Michele, Agodi Antonella
Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, 95123 Catania, Italy.
Department of Ophthalmology, University of Catania, 95123 Catania, Italy.
J Clin Med. 2019 Feb 1;8(2):159. doi: 10.3390/jcm8020159.
Previous studies proposed the application of DNA methylation signatures as clinical biomarkers of age-related macular degeneration (AMD). However, the characterization of Long Interspersed Nuclear Element-1 (LINE-1) methylation levels-a surrogate marker of global DNA methylation-in AMD patients has not been investigated so far. In the present study, we first characterized DNA methyltransferases (DNMTs) and Sirtuin 1 (SIRT1) functions in blood samples of 40 AMD patients and 10 age- and sex-matched controls. Then, we evaluated whether changes in DNMTs functions were associated with different LINE-1 methylation levels in leukocyte DNA. We demonstrated that total DNMTs activity was 48% higher in AMD patients than in controls ( = 0.005). AMD patients also exhibited up-regulation of DNMT1 and DNMT3B expression (FC = 2.6; = 0.003 and FC = 2.4; = 0.018, respectively). In line with increased DNMTs functions, the LINE-1 methylation level was higher in AMD patients than in controls (mean = 69.10%; SE = 0.68 vs. mean = 65.73%; SE = 0.59; = 0.020). All -values were adjusted by Bonferroni correction. In AMD patients, LINE-1 methylation level was positively associated with total DNMTs activity ( = 0.694; < 0.001), DNMT1 ( = 0.579; < 0.001), and DNMT3B ( = 0.521; = 0.001) expression. Our results encourage further large-size prospective research to understand the relationship between LINE-1 methylation and AMD aetiology, and its usefulness in the clinical setting.
先前的研究提出将DNA甲基化特征作为年龄相关性黄斑变性(AMD)的临床生物标志物。然而,迄今为止尚未研究过长散在核元件1(LINE-1)甲基化水平——全球DNA甲基化的替代标志物——在AMD患者中的特征。在本研究中,我们首先对40例AMD患者和10例年龄及性别匹配的对照者的血液样本中的DNA甲基转移酶(DNMTs)和沉默调节蛋白1(SIRT1)功能进行了表征。然后,我们评估了DNMTs功能的变化是否与白细胞DNA中不同的LINE-1甲基化水平相关。我们证明,AMD患者的总DNMTs活性比对照者高48%(P = 0.005)。AMD患者还表现出DNMT1和DNMT3B表达上调(倍数变化分别为2.6;P = 0.003和2.4;P = 0.018)。与DNMTs功能增加一致,AMD患者的LINE-1甲基化水平高于对照者(平均值 = 69.10%;标准误 = 0.68,而平均值 = 65.73%;标准误 = 0.59;P = 0.020)。所有P值均经Bonferroni校正。在AMD患者中,LINE-1甲基化水平与总DNMTs活性(r = 0.694;P < 0.001)、DNMT1(r = 0.579;P < 0.001)和DNMT3B(r = 0.521;P = 0.001)表达呈正相关。我们的结果鼓励进一步开展大规模前瞻性研究,以了解LINE-1甲基化与AMD病因之间的关系及其在临床环境中的实用性。